Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. MYO
MYO logo

MYO Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
1.479
Open
1.450
VWAP
1.34
Vol
1.02M
Mkt Cap
59.12M
Low
1.250
Amount
1.37M
EV/EBITDA(TTM)
--
Total Shares
38.64M
EV
44.69M
EV/OCF(TTM)
--
P/S(TTM)
1.31
Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. The Company develops and markets the MyoPro product line, which is a myoelectric-controlled upper limb brace, or orthosis. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury or other neuromuscular disease or injury. MyoPro senses a patient’s own electromyography (EMG) signals through non-invasive sensors on the arm and can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. MyoPro’s control technology utilizes an advanced human-machine interface based on non-invasive, patented electromyography, or EMG, control technology.
Show More

Events Timeline

(ET)
2026-05-07
17:10:00
Company Expects Q2 2026 Revenue of $10.3M to $10.8M
select
2026-05-07
17:10:00
Myomo Q1 Revenue $10.1M Exceeds Expectations
select
2026-05-04 (ET)
2026-05-04
16:10:00
Myomo Expands Access to MyoPro Device
select
2026-04-20 (ET)
2026-04-20
16:10:00
Myomo Launches Myomo Mobile App
select
2026-03-09 (ET)
2026-03-09
19:40:00
S&P 500 Futures Rally 100 Points, Tech Sector Leads
select
2026-03-09
16:20:00
Myomo Sees Q1 Revenue of $9M-$9.5M, Consensus $10.78M
select
2026-03-09
16:20:00
Myomo Enters Network Agreement with Elevance Health
select
2026-03-09
16:20:00
Company Expects 2026 Revenue to Reach $43M to $46M
select
2026-03-09
16:10:00
Myomo Reports Q4 Revenue of $11.4M
select

News

NASDAQ.COM
2.0
06-16NASDAQ.COM
Regentis Soars After Withdrawing US Listing Application
  • Regentis Stock Surge: Regentis Biomaterials Ltd. (RGNT) saw its shares soar over 500% to close at $9.40 after withdrawing its Form F-1 registration with the SEC, indicating strong market confidence in its strategic decision.
  • GelrinC Product Development: The company's lead product, GelrinC, has received CE Mark approval in Europe, with plans to initiate surgeon training in Q3 2026, which is expected to enhance its market readiness and competitive positioning.
  • Cuprina FDA Approval: Cuprina Holdings (CUPR) received FDA clearance for its MEDIFLY maggots used in wound debridement therapy, leading to a stock increase of over 100%, reflecting its innovative potential and market demand in the medical field.
  • Intellia Positive Results: Intellia Therapeutics (NTLA) jumped over 20% following positive phase 3 results for its hereditary angioedema treatment, with plans for a BLA submission targeting FDA approval in the first half of 2027, showcasing its strong prospects in the biopharmaceutical sector.
NASDAQ.COM
8.5
06-11NASDAQ.COM
Biotech Companies See Significant Stock Gains
  • Parabilis Debut Performance: Parabilis Medicines Inc. saw its stock surge 58% on its Nasdaq debut, pricing 33.5 million shares at $20 each, with expected gross proceeds of approximately $670 million, indicating strong market demand for its innovative drug candidates.
  • Clover Health Legal Victory: Clover Health Investments Corp. achieved a legal victory against the U.S. Department of Health and Human Services, upgrading its PPO plan's star rating from 3.5 to 4.5, with projected total revenues for 2026 between $2.81 billion and $2.92 billion, reflecting a 49% year-over-year growth.
  • Shoulder Innovations Growth: Shoulder Innovations, Inc. reported a net revenue of $16.7 million for Q1, a 65% increase year-over-year, and expects full-year 2026 revenues between $65 million and $68 million, representing a growth of 37% to 44%, showcasing its strong position in the shoulder surgical market.
  • Myomo Stock Surge: Myomo Inc.'s stock rose over 17%, with projected Q2 2026 revenues between $10.3 million and $10.8 million, compared to $9.7 million in Q2 2025, reflecting increasing market demand for its wearable medical robotics products.
seekingalpha
9.5
05-08seekingalpha
Myomo, Inc. Q1 2026 Earnings Call Insights
  • Medicare Policy Breakthrough: Myomo's MyoPro has gained reimbursement under a new Medicare Part B benefit category by CMS, opening access to tens of millions of Medicare beneficiaries and removing the largest historical barrier to adoption, thereby laying the groundwork for future growth.
  • Revenue Growth Momentum: The company reported $10.1 million in revenue for Q1 2026, reflecting a year-over-year increase, with revenue from recurring patient sources rising from 25% to 49%, showcasing success in reducing customer acquisition costs and diversifying revenue streams.
  • International Market Expansion: International revenue increased by 53% year-over-year, while the U.S. O&P channel grew by 79%, indicating enhanced penetration in global markets, particularly through collaboration with Ottobock, which further boosts brand influence and market share.
  • Technological Innovation and Cost Control: The newly launched mobile app reduces MyoPro material costs by approximately 10% per user while enhancing user experience, indicating that the company's ongoing investment in technological innovation will help improve operational efficiency and profitability.
seekingalpha
9.5
05-07seekingalpha
Myomo Q1 Earnings Beat Expectations with Revenue Growth
  • Earnings Highlights: Myomo reported a Q1 GAAP EPS of -$0.07, beating expectations by $0.04, with revenue of $10.1 million reflecting a 3.1% year-over-year growth, indicating solid market performance.
  • Price Increase: The average selling price (ASP) rose to approximately $58,800, up 9% year-over-year, which, despite a slight decrease in revenue units, demonstrates an increase in product value and revenue generation.
  • Customer Growth: The company added 723 patients in Q1, a 7% sequential increase, with the cost per pipeline addition at $2,550, down 16% sequentially, showcasing improved efficiency in customer acquisition.
  • Future Outlook: Myomo expects Q2 revenue to range between $10.3 million and $10.8 million, reaffirming full-year revenue guidance of $43 million to $46 million, reflecting strong confidence in future growth.
seekingalpha
9.5
03-09seekingalpha
Myomo, Inc. Reports Strong Q4 2025 Earnings with Strategic Focus
  • Significant Revenue Growth: Myomo reported $11.4 million in revenue for Q4 2025, reflecting a 26% increase over 2024, with full-year revenue reaching $40.9 million, showcasing the company's success in direct-to-patient marketing and recurring revenue sources.
  • Record Orders: The company received 241 MyoPro orders in the quarter, a 5% increase from Q3, indicating not only rising product demand but also successful penetration in the O&P channel and international markets.
  • Strategic Partnership Expansion: The new multistate agreement with Elevance Health covers 45 million lives, marking a significant advancement in payer contracts that is expected to support future revenue growth.
  • Cautious Future Outlook: Management expects Q1 2026 revenue in the range of $9 million to $9.5 million and sets a full-year target of $43 million to $46 million, reflecting a cautious stance towards market uncertainties while planning to improve gross margins through controlled operating expenses.
seekingalpha
9.5
03-09seekingalpha
Myomo Q4 Earnings Report Analysis
  • Disappointing Earnings: Myomo reported a Q4 non-GAAP EPS of -$0.37, missing expectations by $0.28, indicating ongoing challenges in profitability that could negatively impact investor confidence.
  • Slight Revenue Decline: The company's Q4 revenue of $11.4 million represents a 5.6% year-over-year decline, although it beat expectations by $1 million, the revenue drop reflects weak market demand, potentially affecting future growth prospects.
  • Deteriorating Adjusted EBITDA: The adjusted EBITDA for Q4 2025 was -$1.9 million, a significant decline from $0.2 million in Q4 2024, with a full-year adjusted EBITDA of -$11.5 million compared to -$5.1 million in 2024, indicating a decrease in operational efficiency.
  • Tight Cash Flow Situation: As of December 31, 2025, the company had $18.4 million in cash and cash equivalents, with Q4 operating cash flow at -$1.1 million, a sharp decline from $3.4 million generated in Q4 2024, highlighting liquidity pressures faced by the company.
Wall Street analysts forecast MYO stock price to rise
5 Analyst Rating
Wall Street analysts forecast MYO stock price to rise
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
4.00
Averages
5.75
High
10.00
Current: 0.000
sliders
Low
4.00
Averages
5.75
High
10.00
Alliance Global
Buy
downgrade
$4 -> $3
AI Analysis
2026-03-12
Reason
Alliance Global
Price Target
$4 -> $3
AI Analysis
2026-03-12
downgrade
Buy
Reason
Alliance Global lowered the firm's price target on Myomo to $3 from $4 and keeps a Buy rating on the shares following the Q4 report. The firm cites its lower forecasts and a reduced multiple of sales for the target cut.
H.C. Wainwright
H.C. Wainwright
Buy
downgrade
$5
2025-08-12
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$5
2025-08-12
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Myomo to $5 from $9.50 and keeps a Buy rating on the shares. The firm says that while the company's Q2 ended well, there are warning signs ahead as Myomo reported that the number of patients added to its pipeline was significantly lower than expected.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for MYO
Unlock Now

Valuation Metrics

The current forward P/E ratio for Myomo Inc (MYO.A) is 0.00, compared to its 5-year average forward P/E of -12.47. For a more detailed relative valuation and DCF analysis to assess Myomo Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-12.47
Current PE
0.00
Overvalued PE
1.63
Undervalued PE
-26.57

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-12.47
Current EV/EBITDA
-4.17
Overvalued EV/EBITDA
9.79
Undervalued EV/EBITDA
-34.73

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
2.14
Current PS
0.99
Overvalued PS
3.69
Undervalued PS
0.60

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

Penny stocks bullish
Intellectia · 27 candidates
Region: USPrice: $0.50 - $5.00Rsi Category: moderateRelative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20, PriceAboveMA200, PriceCrossAboveMA20
Ticker
Name
Market Cap$
top bottom
FLNT logo
FLNT
Fluent Inc
79.91M
VSME logo
VSME
VS Media Holdings Ltd
4.67M
AMTD logo
AMTD
AMTD IDEA Group
97.62M
CNVS logo
CNVS
Cineverse Corp
60.05M
TXMD logo
TXMD
TherapeuticsMD Inc
25.46M
CETY logo
CETY
Clean Energy Technologies Inc
12.17M
strong penny stocks
Intellectia · 16 candidates
Price: <= $5.00Relative Vol: >= 1.50Beta: HighRiskMoving Average Relationship: PriceAboveMA5, PriceAboveMA20Week Price Change Pct: >= $0.00Month Price Change Pct: >= $0.00
Ticker
Name
Market Cap$
top bottom
DTSS logo
DTSS
Datasea Intelligent Technology Ltd
10.45M
VRA logo
VRA
Vera Bradley Inc
98.40M
SXTC logo
SXTC
China SXT Pharmaceuticals Inc
86.37M
NXGL logo
NXGL
Nexgel Inc
5.44M
NRDY logo
NRDY
Nerdy Inc
182.31M
NVX logo
NVX
NOVONIX Ltd
146.58M
what compainies should i look at
Intellectia · 87 candidates
Market Cap: <= 2.00BRegion: USPrice: <= $5.00Relative Vol: >= 1.50Moving Average Relationship: PriceAboveMA5, PriceCrossAboveMA5Week Price Change Pct: >= $0.00One Week Predict Return: >= 0.0%
Ticker
Name
Market Cap$
top bottom
LASE logo
LASE
Laser Photonics Corp
119.56M
HCAT logo
HCAT
Health Catalyst Inc
142.62M
NWL logo
NWL
Newell Brands Inc
1.58B
DLTH logo
DLTH
Duluth Holdings Inc
126.59M
MYO logo
MYO
Myomo Inc
49.46M
CALC logo
CALC
CalciMedica Inc
16.75M
good penny stocks soon to blow up
Intellectia · 26 candidates
Market Cap: <= 300.00MPrice: $0.50 - $5.00Volume: >= 500,000Relative Vol: >= 1.50Moving Average Relationship: PriceAboveMA20, PriceAboveMA60, PriceCrossAboveMA20
Ticker
Name
Market Cap$
top bottom
VVOS logo
VVOS
Vivos Therapeutics Inc
12.01M
ELOG logo
ELOG
Eastern International Ltd
15.53M
BCDA logo
BCDA
BioCardia Inc
11.72M
YXT logo
YXT
YXT.Com Group Holding Ltd
32.36M
SCAG logo
SCAG
Scage Future
61.22M
GLXG logo
GLXG
Galaxy Payroll Group Ltd
6.62M
best penny stocks
Intellectia · 65 candidates
Market Cap: <= 300.00MRegion: USPrice: $0.50 - $5.00Volume: >= 100,000Quarter Revenue Yoy Growth: >= 0.0%Gross Margin: >= 0.00Annual Revenue Yoy Growth: >= 0.0%
Ticker
Name
Market Cap$
top bottom
TRNR logo
TRNR
Interactive Strength Inc
1.87M
VMAR logo
VMAR
Vision Marine Technologies Inc
2.15M
MYSZ logo
MYSZ
My Size Inc
2.99M
SNOA logo
SNOA
Sonoma Pharmaceuticals Inc
3.96M
AMBO logo
AMBO
Ambow Education Holding Ltd
6.84M
ACON logo
ACON
Aclarion Inc
8.08M
stocks to buy under 1 $ for Short term Gains
Intellectia · 12 candidates
Price: $0.10 - $1.00Volume: >= 300,000Beta: HighRiskList Exchange: XNYS, XNAS, XASEWeek Price Change Pct: >= $5.00
Ticker
Name
Market Cap$
top bottom
ASNS logo
ASNS
Actelis Networks Inc
2.81M
TNYA logo
TNYA
Tenaya Therapeutics Inc
192.26M
NOTV logo
NOTV
Inotiv Inc
12.70M
SGN logo
SGN
Signing Day Sports Inc
6.37M
HOWL logo
HOWL
Werewolf Therapeutics Inc
30.67M
ADV logo
ADV
Advantage Solutions Inc
209.60M
list of strong buy stocks under $3.00
Intellectia · 94 candidates
Price: <= $3.00Analyst Consensus: Strong Buy
Ticker
Name
Market Cap$
top bottom
AKTX logo
AKTX
Akari Therapeutics PLC
9.32M
PSTV logo
PSTV
Plus Therapeutics Inc
52.05M
RVPH logo
RVPH
Reviva Pharmaceuticals Holdings Inc
38.21M
INTS logo
INTS
Intensity Therapeutics Inc
23.85M
MREO logo
MREO
Mereo BioPharma Group PLC
84.34M
ATOS logo
ATOS
Atossa Therapeutics Inc
77.93M
stock to buy under 1$ for 2026
Intellectia · 9 candidates
Market Cap: >= 20.00MPrice: <= $1.00Beta: ModerateRisk, HighRiskWeekly Average Turnover: >= 300,000Annual Revenue Yoy Growth: >= 0.0%
Ticker
Name
Market Cap$
top bottom
ASST logo
ASST
Strive Inc
1.11B
CAN logo
CAN
Canaan Inc
498.64M
AGL logo
AGL
agilon health inc
395.14M
REI logo
REI
Ring Energy Inc
203.08M
IXHL logo
IXHL
Incannex Healthcare Inc
123.43M
ARAY logo
ARAY
Accuray Inc
91.78M
Best stock under 3.50 that will 3x
Intellectia · 29 candidates
Market Cap: <= 2.00BPrice: <= $3.50Beta: HighRiskRevenue 5yr Cagr: >= 20Annual Eps Yoy Growth: >= 20.0%
Ticker
Name
Market Cap$
top bottom
CLVT logo
CLVT
Clarivate PLC
1.86B
BITF logo
BITF
Bitfarms Ltd
1.61B
BLND logo
BLND
Blend Labs Inc
732.49M
SNDL logo
SNDL
SNDL Inc
406.85M
LCTX logo
LCTX
Lineage Cell Therapeutics Inc
382.34M
SLQT logo
SLQT
SelectQuote Inc
283.31M

Whales Holding MYO

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Myomo Inc (MYO) stock price today?

The current price of MYO is 1.28 USD — it has decreased -9.86

What is Myomo Inc (MYO)'s business?

Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. The Company develops and markets the MyoPro product line, which is a myoelectric-controlled upper limb brace, or orthosis. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury or other neuromuscular disease or injury. MyoPro senses a patient’s own electromyography (EMG) signals through non-invasive sensors on the arm and can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. MyoPro’s control technology utilizes an advanced human-machine interface based on non-invasive, patented electromyography, or EMG, control technology.

What is the price predicton of MYO Stock?

Wall Street analysts forecast MYO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MYO is5.75 USD with a low forecast of 4.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Myomo Inc (MYO)'s revenue for the last quarter?

Myomo Inc revenue for the last quarter amounts to 10.11M USD, increased 2.86

What is Myomo Inc (MYO)'s earnings per share (EPS) for the last quarter?

Myomo Inc. EPS for the last quarter amounts to -0.07 USD, decreased -12.50

How many employees does Myomo Inc (MYO). have?

Myomo Inc (MYO) has 194 emplpoyees as of June 20 2026.

What is Myomo Inc (MYO) market cap?

Today MYO has the market capitalization of 59.12M USD.